CRISPR Therapeutics AG (CRSP): Price and Financial Metrics
CRSP Price/Volume Stats
Current price | $68.16 | 52-week high | $91.10 |
Prev. close | $70.16 | 52-week low | $37.55 |
Day low | $67.52 | Volume | 1,602,521 |
Day high | $70.12 | Avg. volume | 1,966,600 |
50-day MA | $73.47 | Dividend yield | N/A |
200-day MA | $59.27 | Market Cap | 5.47B |
CRSP Stock Price Chart Interactive Chart >
CRSP POWR Grades
- CRSP scores best on the Growth dimension, with a Growth rank ahead of 83.31% of US stocks.
- The strongest trend for CRSP is in Stability, which has been heading down over the past 26 weeks.
- CRSP's current lowest rank is in the Stability metric (where it is better than 1.05% of US stocks).
CRSP Stock Summary
- Of note is the ratio of CRISPR THERAPEUTICS AG's sales and general administrative expense to its total operating expenses; only 4.62% of US stocks have a lower such ratio.
- With a price/sales ratio of 29.23, CRISPR THERAPEUTICS AG has a higher such ratio than 95.37% of stocks in our set.
- Revenue growth over the past 12 months for CRISPR THERAPEUTICS AG comes in at 1,106.49%, a number that bests 99.3% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to CRISPR THERAPEUTICS AG, a group of peers worth examining would be RLAY, VERV, RVMD, CLDX, and NRIX.
- Visit CRSP's SEC page to see the company's official filings. To visit the company's web site, go to www.crisprtx.com.
CRSP Valuation Summary
- CRSP's price/earnings ratio is -14.1; this is 148.37% lower than that of the median Healthcare stock.
- Over the past 88 months, CRSP's EV/EBIT ratio has gone down 4.3.
Below are key valuation metrics over time for CRSP.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
CRSP | 2023-12-29 | 29.2 | 2.9 | -14.1 | -13.0 |
CRSP | 2023-12-28 | 30.0 | 3.0 | -14.4 | -13.3 |
CRSP | 2023-12-27 | 30.4 | 3.0 | -14.6 | -13.5 |
CRSP | 2023-12-26 | 30.5 | 3.0 | -14.7 | -13.6 |
CRSP | 2023-12-22 | 29.7 | 2.9 | -14.3 | -13.2 |
CRSP | 2023-12-21 | 28.3 | 2.8 | -13.6 | -12.5 |
CRSP Growth Metrics
- Its year over year net income to common stockholders growth rate is now at 179.43%.
- Its 5 year net cashflow from operations growth rate is now at 187.22%.
- Its 5 year cash and equivalents growth rate is now at 180.78%.
The table below shows CRSP's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 14.091 | -468.451 | -680.848 |
2022-06-30 | 14.821 | -444.562 | -633.452 |
2022-03-31 | 915.364 | 504.396 | 311.607 |
2021-12-31 | 914.963 | 538.972 | 377.661 |
2021-09-30 | 902.434 | 543.798 | 411.87 |
2021-06-30 | 901.758 | 549.427 | 446.584 |
CRSP's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CRSP has a Quality Grade of C, ranking ahead of 73.06% of graded US stocks.
- CRSP's asset turnover comes in at 0.441 -- ranking 101st of 681 Pharmaceutical Products stocks.
- CDTX, NVS, and SEEL are the stocks whose asset turnover ratios are most correlated with CRSP.
The table below shows CRSP's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.441 | 1 | 0.579 |
2021-03-31 | 0.001 | 1 | -0.839 |
2020-12-31 | 0.001 | 1 | -1.179 |
2020-09-30 | 0.067 | 1 | -1.230 |
2020-06-30 | 0.301 | 1 | 0.242 |
2020-03-31 | 0.352 | 1 | 0.539 |
CRSP Price Target
For more insight on analysts targets of CRSP, see our CRSP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $162.94 | Average Broker Recommendation | 1.55 (Moderate Buy) |
CRISPR Therapeutics AG (CRSP) Company Bio
CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The company is based in Basel, Switzerland.
Latest CRSP News From Around the Web
Below are the latest news stories about CRISPR THERAPEUTICS AG that investors may wish to consider to help them evaluate CRSP as an investment opportunity.
AI and Automation Leaders for 2024: 7 Stocks to Stay Ahead of the Robot UprisingIt’s time for investors to ditch the search for the mythical crystal ball and instead embrace the algorithms when deciphering the best AI stock for your needs. |
3 Healthcare Technology Stocks to Improve Lives in 2024Healthcare technology is one of 2024's top investment trends, and investors looking for long-term upside should check out these top stocks. |
Could CRISPR Therapeutics Stock Help You Become a Millionaire?There are plenty of reasons to be optimistic about CRISPR's future. |
Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction. |
6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing TherapyShould you buy CRISPR's stock on the dip? |
CRSP Price Returns
1-mo | -23.52% |
3-mo | 8.88% |
6-mo | 50.17% |
1-year | 50.86% |
3-year | -38.44% |
5-year | 90.82% |
YTD | 8.88% |
2023 | 54.00% |
2022 | -46.36% |
2021 | -50.51% |
2020 | 151.39% |
2019 | 113.18% |
Continue Researching CRSP
Here are a few links from around the web to help you further your research on CRISPR Therapeutics AG's stock as an investment opportunity:CRISPR Therapeutics AG (CRSP) Stock Price | Nasdaq
CRISPR Therapeutics AG (CRSP) Stock Quote, History and News - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...